AbbVievs.Johnson & Johnson
ABBV vs JNJ · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Johnson & Johnson is about 1.4× larger than AbbVie by market cap; Johnson & Johnson trades at the lower P/E (29.9 vs 70.2); year to date, Johnson & Johnson leads (+31.9% vs +15.8%).
Side by side
| ABBV | JNJ | |
|---|---|---|
| Market cap | $443B | $630B |
| Price | $265.79 | $273.14 |
| Today | +0.5% | +0.0% |
| Return YTD | +15.8% | +31.9% |
| Return 1Y | +25.6% | +52.3% |
| P/E | 70.2 | 29.9 |
| P/S | 6.9 | 6.4 |
| P/B | 312.1 | 7.4 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AbbVieABBV
Skyrizi and Rinvoq carry the immunology franchise. Oncology and neuroscience follow, plus the aesthetics business built around Botox.
Full ABBV profile →Johnson & JohnsonJNJ
Two businesses under one name: Innovative Medicine, which covers immunology and oncology drugs, and MedTech, which makes medical devices and surgical equipment.
Full JNJ profile →More ABBV & JNJ comparisons
Other head-to-heads in the Big pharma segment.